Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
Long GV. et al, (2017), EUROPEAN JOURNAL OF CANCER, 72, S128 - S129
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A. et al, (2017), PLoS Med, 14, e1002230 - e1002230
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Middleton MR. et al, (2017), British Journal of Cancer
Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment
Beusterien K. et al, (2017), Journal of Cancer Therapy, 8, 37-50
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
Goding C. et al, (2016), Genes and Development
First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
Postel-Vinay S. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S7 - S8
Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF-A, in patients with advanced solid tumors
Dawson K. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S133 - S133
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.
Lu M. et al, (2016), Cancer cell, 30, 822 - 823
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Gupta A. et al, (2016), British Journal of Cancer
A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B
Eyre TA. et al, (2016), Annals of Oncology, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), ANNALS OF ONCOLOGY, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), Annals of Oncology, 27
Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM. et al, (2016), Eur Radiol, 26, 3519 - 3533
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Garbe C. et al, (2016), Eur J Cancer, 63, 201 - 217
Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.
Findlay JM. et al, (2016), United European gastroenterology journal, 4, 485 - 492
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2016), Target Oncol, 11, 557 - 563
Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial
Harrington K. et al, (2016), MELANOMA RESEARCH, 26, E4 - E5
Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka R. et al, (2016), MELANOMA RESEARCH, 26, E36 - E37